If its study of lung denervation hits, Nuvaira could get US approval and maybe swing a trade sale.
The Danish group tops the list, while Ardelyx could get its first nod for tenapanor, and Xeris gets a second shot with its hypoglycaemia rescue pen.
Astrazeneca’s battle with Glaxosmithkline is set to ramp up next year with Breztri Aerosphere mortality data in COPD on the horizon.
One of the biggest drugs of the year, Abbvie’s Jak inhibitor upadacitinib, could get the nod in August.
A strong second quarter pushed Novartis’s stock up 5% this morning, but Kymriah continues to look weak, and the jury is still out on Zolgensma.
Astrazeneca hopes that its new COPD triplet can gain share from Glaxosmithkline’s rival, but it is not planning a price war.
With the company’s Molgradex failing to beat standard of care in a rare lung disorder, the premise behind this project looks questionable.
Payment of an overdue $120m Astrazeneca milestone, plus two other obligations, has been met through a loan facility with undisclosed terms.
Astrazeneca has made another push into artificial intelligence, but admits that it will be some time before it knows whether the technology has helped its drug discovery…